Discovery of indolizines containing triazine moiety as new leads for the development of antitumoral agents targeting mitotic events.
Bioorg Med Chem Lett 2015;
25:3975-9. [PMID:
26227778 DOI:
10.1016/j.bmcl.2015.07.025]
[Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 07/09/2015] [Accepted: 07/11/2015] [Indexed: 11/19/2022]
Abstract
A new family of 3-aroylindolizines bearing a dimethoxytriazine unit in their position 1 was designed, synthesized and evaluated for their ability to inhibit tubulin polymerization and cellular growth in vitro. Compound 39 was the best candidate in the current study with a GI50 value of 870 nM on SNB-75 CNS cancer cells and of 920 nM on MDA-MB-231/ATCC breast cancer cells. The standard NCI Compare results indicated that indolizine 39 may target PLK1 (polo-like kinase 1).
Collapse